CHRS
Price
$0.83
Change
+$0.02 (+2.47%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
92.84M
55 days until earnings call
TSBX
Price
$0.36
Change
+$0.01 (+2.86%)
Updated
Jun 6, 04:51 PM (EDT)
Capitalization
8.35M
68 days until earnings call
Interact to see
Advertisement

CHRS vs TSBX

Header iconCHRS vs TSBX Comparison
Open Charts CHRS vs TSBXBanner chart's image
Coherus Oncology
Price$0.83
Change+$0.02 (+2.47%)
Volume$8.9K
Capitalization92.84M
Turnstone Biologics
Price$0.36
Change+$0.01 (+2.86%)
Volume$5.71K
Capitalization8.35M
CHRS vs TSBX Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. TSBX commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and TSBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (CHRS: $0.80 vs. TSBX: $0.35)
Brand notoriety: CHRS and TSBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 72% vs. TSBX: 73%
Market capitalization -- CHRS: $92.84M vs. TSBX: $8.35M
CHRS [@Biotechnology] is valued at $92.84M. TSBX’s [@Biotechnology] market capitalization is $8.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileTSBX’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • TSBX’s FA Score: 1 green, 4 red.
According to our system of comparison, TSBX is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while TSBX’s TA Score has 6 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • TSBX’s TA Score: 6 bullish, 1 bearish.
According to our system of comparison, TSBX is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -0.15% price change this week, while TSBX (@Biotechnology) price change was +8.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

TSBX is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($92.8M) has a higher market cap than TSBX($8.35M). TSBX YTD gains are higher at: -29.503 vs. CHRS (-41.971). CHRS has higher annual earnings (EBITDA): 37.3M vs. TSBX (-76.82M). CHRS has more cash in the bank: 97.7M vs. TSBX (45.3M). TSBX has less debt than CHRS: TSBX (1.7M) vs CHRS (270M). CHRS has higher revenues than TSBX: CHRS (304M) vs TSBX (0).
CHRSTSBXCHRS / TSBX
Capitalization92.8M8.35M1,111%
EBITDA37.3M-76.82M-49%
Gain YTD-41.971-29.503142%
P/E Ratio1.89N/A-
Revenue304M0-
Total Cash97.7M45.3M216%
Total Debt270M1.7M15,892%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
18

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSTSBX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CNIKF0.710.02
+3.30%
Canada Nickel Co Inc
LGGNY17.370.18
+1.05%
Legal & General Group Plc
NPSNY60.810.16
+0.26%
Naspers Ltd.
YAMCY7.12N/A
N/A
Yamaha Corp.
UNRG0.03N/A
-3.57%
United Energy Corp.

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+0.48%
XENE - CHRS
40%
Loosely correlated
+0.79%
ADCT - CHRS
39%
Loosely correlated
-4.18%
ARRY - CHRS
39%
Loosely correlated
+6.16%
AXON - CHRS
38%
Loosely correlated
+1.08%
AMRN - CHRS
35%
Loosely correlated
-0.46%
More

TSBX and

Correlation & Price change

A.I.dvisor tells us that TSBX and CHRS have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TSBX and CHRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSBX
1D Price
Change %
TSBX100%
+1.10%
CHRS - TSBX
26%
Poorly correlated
+0.48%
ARQT - TSBX
26%
Poorly correlated
+1.81%
FULC - TSBX
25%
Poorly correlated
+1.07%
DYN - TSBX
25%
Poorly correlated
+4.40%
LGND - TSBX
24%
Poorly correlated
+0.27%
More